Recently, according to the Guangdong Province 2025 Third Batch of High-Tech Enterprise Recognition Filing List published on the National High-tech Enterprise Certification and Management Work Network, Cell Valley Group's wholly-owned subsidiary — Guangdong JUNJO Pharma Co., Ltd successfully passed the recognition and has been officially filed as a National High-Tech Enterprise.

Guangdong JUNJO Pharma Co., Ltd is an important subsidiary within the Cell Valley system, focusing on the research and development, engineering scale-up, and industrial production of viral vectors and core technologies related to Cell and Gene Therapy (CGT). Since its establishment, the company has continuously invested R&D resources around key CGT foundational capabilities, forming systematic technological accumulation in production processes, quality control systems, and large-scale manufacturing.

High-Tech Enterprise recognition is a comprehensive uation of an enterprise's technological innovation capabilities, independent intellectual property rights, R&D management systems, and technological achievement transformation capabilities. This successful passage of the National High-Tech Enterprise recognition signifies that  Guangdong JUNJO Pharma has received national authoritative recognition for its core technical strength, R&D organization capabilities, and industrialization level, further consolidating its specialized positioning within the cell and gene therapy industry chain.

In the future, Guangdong JUNJO Pharma will continue to strengthen key technology breakthroughs and platform capability construction, deepen synergy with Shenzhen Cell Valley in technology, industry, and resource dimensions, actively serve the development of the biomedical and high-end manufacturing industries in the Guangdong-Hong Kong-Macao Greater Bay Area, and provide solid support for promoting the standardization, large-scale, and high-quality development of cell and gene therapy-related technologies.